BioCryst is profitable now. The 2027 readout decides what comes next

The technology

BioCryst's business rests on one mechanism. Plasma kallikrein drives the attacks of hereditary angioedema (HAE), and Orladeyo (berotralstat) is an oral, once-daily pill that blocks it. The company calls it the first oral, once-daily plasma kallikrein inhibitor. In the second quarter of 2026 it sold $158.2 million, and the company guides to $625 million to $645 million for the year.

Navenibart hits the same target with a long-acting injection. BioCryst gained it by buying Astria Therapeutics on January 23, 2026, and is testing doses every three and every six months in ALPHA-ORBIT, a phase 3 trial that completed enrollment in June. Early data from ALPHA-STAR, the phase 1b/2 study, showed attack reductions across subgroups in 29 adults with no serious treatment-emergent adverse events. That is a small, uncontrolled base.

The third program, BCX17725, targets KLK5 in Netherton syndrome, a rare skin disease. It is in part 4 of a phase 1 trial with up to 12 patients.

The odds

Orladeyo carries commercial risk, not clinical risk. Its pediatric pellets for ages 2 to under 12 began shipping the week of August 3, with 47 prescriptions written by then.

Navenibart is the real test. The BIO/Informa/QLS study of 2011 to 2020 found rare disease drugs in phase 3 reached a filing 60.4% of the time, and filed rare disease drugs were approved 93.6% of the time. Orladeyo itself shows the target works, which helps, but long dosing intervals still need to show attack control holds through months 3 to 6. Top-line data are due in the third quarter of 2027.

BCX17725 is early. A phase 1 program has historically moved to phase 2 52.0% of the time.

The money

BioCryst is profitable on a GAAP basis in a normal quarter. It reported net income of $78.4 million in the second quarter, though $55.7 million of revenue came from licensing European navenibart rights to Neopharmed Gentili. Total revenue guidance is $690 million to $715 million.

Cash and investments were $354.0 million at June 30. The company also owes $400 million under a Blackstone loan that matures in January 2031 at SOFR plus 4.50%. The 10-Q says resources are enough for at least 12 months. Spending is coming down: BioCryst cut 2026 non-GAAP operating expense guidance to $420 million to $440 million after deciding to close its Birmingham discovery site.

The risks

The first is concentration. Nearly all product revenue is Orladeyo, and Annora Pharma has filed for a generic version, challenging four patents that run to May 2040. Six unchallenged patents expire in 2035. The case is early.

The second is competition. Fierce Biotech pointed to KalVista's oral drug Ekterly, approved last year, in the same drug class. U.S. Orladeyo growth slowed from 21% on a comparable basis in the first quarter to 10% in the second.

The third is strategy. BioCryst has ended internal discovery and will rely on in-licensing. That works only if management finds and prices good assets.

Our read

BioCryst has made itself simpler: a U.S. HAE company with a profitable pill, one phase 3 bet and cash to acquire more. The quarterly numbers will be noisy because of license revenue and acquisition charges, so the cleaner signal is comparable U.S. Orladeyo growth. Pellet uptake is a modest tailwind. The value question sits in 2027, when navenibart either gives BioCryst a second HAE franchise or leaves it defending a single drug against generics and newer rivals. The November 4 results are the next checkpoint.